2026-06-27T01:25:34Zhttps://docta.ucm.es/rest/oai/request

oai:docta.ucm.es:20.500.14352/44342024-07-04T13:43:58Zcom_20.500.14352_14col_20.500.14352_15

Martínez De La Casa Fernández-Borrella, José María Sáenz Francés, Federico Morales Fernández, Laura Perucho González, Lucía Méndez Hernández, Carmen Dora Fernández Vidal, Ana M. García Sáenz, Sofía Sánchez Jean, Rubén García Feijoo, Julián 2023-06-16T14:15:59Z 2023-06-16T14:15:59Z 2021-08-02 Martínez De La Casa Fernández-Borrella, J. M., Sáenz Francés, F., Morales Fernández, L. et al. «Clinical Outcomes of Combined Preserflo Microshunt Implantation and Cataract Surgery in Open-Angle Glaucoma Patients». Scientific Reports, vol. 11, n.o 1, agosto de 2021, p. 15600. DOI.org (Crossref), https://doi.org/10.1038/s41598-021-95217-x. 2045-2322 10.1038/s41598-021-95217-x https://hdl.handle.net/20.500.14352/4434 https://doi.org/10.1038/s41598-021-95217-x http://www.nature.com/srep/index.html To assess the effectiveness and safety of the Preserflo Microshunt (PMS) implantation combined with cataract surgery in open-angle glaucoma (OAG) patients. Retrospective, open-label study conducted on insufficiently controlled OAG patients, who underwent a PMS implant procedure with mitomycin-C 0.2%, either alone or in combination with cataract surgery, and were followed for at least 12 months. Success was defined as an intraocular pressure (IOP) ≤ 18 mmHg and a reduction of at least 20% without (complete) or with (qualified) hypotensive medication. Fifty-eight eyes were included in the study, 35 eyes underwent PMS alone and 23 underwent PMS + Phaco. In the overall study sample, mean IOP was significantly lowered from 21.5 ± 3.3 mmHg at baseline to 14.6 ± 3.5 mmHg at month 12 (p < 0.0001). The IOP was significantly reduced in both groups; p < 0.0001 each, respectively. Ocular hypotensive medication was significantly reduced (p < 0.0001) in both groups. No significant differences were observed in IOP lowering or medication reduction between groups. At month 12, 62.1% eyes were considered as complete success and 82.8% eyes as qualified success. The most common adverse events were device close-to-endothelium, conjunctival fibrosis, and wound leakage. PMS, either alone or in combination with phacoemulsification, may be considered as a valuable option for treating OAG patients. eng https://creativecommons.org/licenses/by/3.0/es/ open access Atribución 3.0 España Clinical outcomes of combined Preserflo Microshunt implantation and cataract surgery in open-angle glaucoma patients journal article